PDE4A: A Potential Drug Target for Neurological Disorders (G5141)

Target Name: PDE4A

NCBI ID: G5141

PDE4A

PDE4A: A Potential Drug Target for Neurological Disorders

The Paral line-dependent dysplasia (PDE4A) gene is a member of the PDE4 family, which plays a crucial role in the development and maintenance of the nervous system. PDE4A gene has been implicated in various neurological and psychiatric disorders, including epilepsy, schizophrenia , and mood disorders. In addition, PDE4A has also been identified as a potential drug target and biomarker for several diseases. In this article, we will discuss the PDE4A gene, its function, and its potential as a drug target.

Functional Analysis of PDE4A

PDE4A is a 14 kDa protein that is expressed in various tissues, including brain, heart, and kidney. It is involved in the regulation of cellular signaling pathways, including G-protein-coupled receptor (GPCR) signaling, which is a critical pathway involved in many physiological processes, including neuronal communication and behavior.

PDE4A is a GPCR-coupled receptor, which means that it interacts with GPCRs on the surface of neurons and other cells. GPCRs are a family of transmembrane proteins that play a central role in cellular signaling, including the regulation of sensory perception, neurotransmitter release, and cell survival. PDE4A is known to interact with several GPCRs, including the GPCR known as GRIN2.

GRIN2 is a GPCR that is involved in the regulation of neuronal excitability and synaptic plasticity. PDE4A has been shown to interact with GRIN2 and regulate its activity, which can lead to changes in neuronal excitability and synaptic plasticity.

PDE4A Interactions with Other Genes

PDE4A has been shown to interact with several other genes, including the gene for the neurotransmitter dopamine. PDE4A has been shown to regulate the release of dopamine from neurons, which is involved in many neurological and psychiatric disorders, including Parkinson's disease, addiction, and depression.

PDE4A has also been shown to interact with the gene for the neurotransmitter GABA. GABA is an inhibitory neurotransmitter that is involved in the regulation of neuronal excitability and the modulation of brain activity. PDE4A has also been shown to regulate the release of GABA from neurons, which can affect the levels of inhibition in the brain and contribute to the symptoms of epilepsy and schizophrenia.

PDE4A as a Drug Target

PDE4A has been identified as a potential drug target due to its involvement in the regulation of cellular signaling pathways and its role in the development of various neurological and psychiatric disorders. Several studies have shown that blocking PDE4A activity can lead to the reversal of the effects of other drugs, such as antipsychotic medications, which are used to treat disorders with hyperactive neurons, including schizophrenia and bipolar disorder.

One of the potential strategies for targeting PDE4A is the use of small molecules, such as those that can inhibit the activity of PDE4A. Several studies have shown that inhibitors of PDE4A activity have the potential to treat various neurological and psychiatric disorders, including epilepsy, schizophrenia , and mood disorders.

Another approach to targeting PDE4A is the use of monoclonal antibodies, which are laboratory-produced molecules that can bind to a specific protein with high affinity. PDE4A has been shown to be a good candidate for monoclonal antibodies, and several studies have shown that these antibodies have the potential to treat various neurological and psychiatric disorders, including epilepsy, schizophrenia, and

Protein Name: Phosphodiesterase 4A

Functions: Hydrolyzes the second messenger 3',5'-cyclic AMP (cAMP), which is a key regulator of many important physiological processes

The "PDE4A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PDE4A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets